Modeling the impact of prevention policies on future diabetes prevalence in the United States: 2010-2030
Although diabetes is one of the most costly and rapidly increasing serious chronic diseases worldwide, the optimal mix of strategies to reduce diabetes prevalence has not been determined. Using a dynamic model that incorporates national data on diabetes prevalence and incidence, migration, mortality...
Gespeichert in:
Veröffentlicht in: | Population health metrics 2013-09, Vol.11 (1), p.18-18, Article 18 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 18 |
---|---|
container_issue | 1 |
container_start_page | 18 |
container_title | Population health metrics |
container_volume | 11 |
creator | Gregg, Edward W Boyle, James P Thompson, Theodore J Barker, Lawrence E Albright, Ann L Williamson, David F |
description | Although diabetes is one of the most costly and rapidly increasing serious chronic diseases worldwide, the optimal mix of strategies to reduce diabetes prevalence has not been determined.
Using a dynamic model that incorporates national data on diabetes prevalence and incidence, migration, mortality rates, and intervention effectiveness, we project the effect of five hypothetical prevention policies on future US diabetes rates through 2030: 1) no diabetes prevention strategy; 2) a "high-risk" strategy, wherein adults with both impaired fasting glucose (IFG) (fasting plasma glucose of 100-124 mg/dl) and impaired glucose tolerance (IGT) (2-hour post-load glucose of 141-199 mg/dl) receive structured lifestyle intervention; 3) a "moderate-risk" strategy, wherein only adults with IFG are offered structured lifestyle intervention; 4) a "population-wide" strategy, in which the entire population is exposed to broad risk reduction policies; and 5) a "combined" strategy, involving both the moderate-risk and population-wide strategies. We assumed that the moderate- and high-risk strategies reduce the annual diabetes incidence rate in the targeted subpopulations by 12.5% through 2030 and that the population-wide approach would reduce the projected annual diabetes incidence rate by 2% in the entire US population.
We project that by the year 2030, the combined strategy would prevent 4.6 million incident cases and 3.6 million prevalent cases, attenuating the increase in diabetes prevalence by 14%. The moderate-risk approach is projected to prevent 4.0 million incident cases, 3.1 million prevalent cases, attenuating the increase in prevalence by 12%. The high-risk and population approaches attenuate the projected prevalence increases by 5% and 3%, respectively. Even if the most effective strategy is implemented (the combined strategy), our projections indicate that the diabetes prevalence rate would increase by about 65% over the 23 years (i.e., from 12.9% in 2010 to 21.3% in 2030).
While implementation of appropriate diabetes prevention strategies may slow the rate of increase of the prevalence of diabetes among US adults through 2030, the US diabetes prevalence rate is likely to increase dramatically over the next 20 years. Demand for health care services for people with diabetes complications and diabetes-related disability will continue to grow, and these services will need to be strengthened along with primary diabetes prevention efforts. |
doi_str_mv | 10.1186/1478-7954-11-18 |
format | Article |
fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3853008</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A534669468</galeid><sourcerecordid>A534669468</sourcerecordid><originalsourceid>FETCH-LOGICAL-c588t-159360304d2b46749536237bf4866a0d74612db41730732a918387b6782377ea3</originalsourceid><addsrcrecordid>eNptkktv1TAQhS0EoqWwZocssYFFWr9iOywqVRWPSkVIlK4tJ5nc6yqxg-1U8O9xaLn0IuSF7ZnvnNGMBqGXlBxTquUJFUpXqqlFRWlF9SN0uIs8fvA-QM9SuiGEsRJ6ig6YIEJx1hyi7efQw-j8BuctYDfNtss4DHiOcAs-u-DxHEbXOUi4vIclLxFw72wLuYRWzI7gu6L1vy2uvcvQ46tsS_4dZoSSihFOnqMngx0TvLi_j9D1h_ffzj9Vl18-XpyfXVZdrXWuaN1wWXDRs1ZIJZqaS8ZVOwgtpSW9EpKyvhVUcVI6sA3VXKtWKl0oBZYfodM733lpJ-i70kS0o5mjm2z8aYJ1Zj_j3dZswq3huuaE6GLw5t4ghu8LpGwmlzoYR-shLMlQUTe0VlKxgr7-B70JS_SlvZXSgmnOm7_UpkzKOD-EUrdbTc1ZzYWUjZBr2eP_UOX0MLkueBhcie8J3u4JCpPhR97YJSVzcfV1nz25Y7sYUoow7OZBiVkXyayrYtZVKV9DV8Wrh2Pc8X82h_8Cva--Fw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1458428339</pqid></control><display><type>article</type><title>Modeling the impact of prevention policies on future diabetes prevalence in the United States: 2010-2030</title><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central Open Access</source><source>PubMed Central</source><source>Springer Nature OA/Free Journals</source><source>SpringerLink Journals - AutoHoldings</source><creator>Gregg, Edward W ; Boyle, James P ; Thompson, Theodore J ; Barker, Lawrence E ; Albright, Ann L ; Williamson, David F</creator><creatorcontrib>Gregg, Edward W ; Boyle, James P ; Thompson, Theodore J ; Barker, Lawrence E ; Albright, Ann L ; Williamson, David F</creatorcontrib><description>Although diabetes is one of the most costly and rapidly increasing serious chronic diseases worldwide, the optimal mix of strategies to reduce diabetes prevalence has not been determined.
Using a dynamic model that incorporates national data on diabetes prevalence and incidence, migration, mortality rates, and intervention effectiveness, we project the effect of five hypothetical prevention policies on future US diabetes rates through 2030: 1) no diabetes prevention strategy; 2) a "high-risk" strategy, wherein adults with both impaired fasting glucose (IFG) (fasting plasma glucose of 100-124 mg/dl) and impaired glucose tolerance (IGT) (2-hour post-load glucose of 141-199 mg/dl) receive structured lifestyle intervention; 3) a "moderate-risk" strategy, wherein only adults with IFG are offered structured lifestyle intervention; 4) a "population-wide" strategy, in which the entire population is exposed to broad risk reduction policies; and 5) a "combined" strategy, involving both the moderate-risk and population-wide strategies. We assumed that the moderate- and high-risk strategies reduce the annual diabetes incidence rate in the targeted subpopulations by 12.5% through 2030 and that the population-wide approach would reduce the projected annual diabetes incidence rate by 2% in the entire US population.
We project that by the year 2030, the combined strategy would prevent 4.6 million incident cases and 3.6 million prevalent cases, attenuating the increase in diabetes prevalence by 14%. The moderate-risk approach is projected to prevent 4.0 million incident cases, 3.1 million prevalent cases, attenuating the increase in prevalence by 12%. The high-risk and population approaches attenuate the projected prevalence increases by 5% and 3%, respectively. Even if the most effective strategy is implemented (the combined strategy), our projections indicate that the diabetes prevalence rate would increase by about 65% over the 23 years (i.e., from 12.9% in 2010 to 21.3% in 2030).
While implementation of appropriate diabetes prevention strategies may slow the rate of increase of the prevalence of diabetes among US adults through 2030, the US diabetes prevalence rate is likely to increase dramatically over the next 20 years. Demand for health care services for people with diabetes complications and diabetes-related disability will continue to grow, and these services will need to be strengthened along with primary diabetes prevention efforts.</description><identifier>ISSN: 1478-7954</identifier><identifier>EISSN: 1478-7954</identifier><identifier>DOI: 10.1186/1478-7954-11-18</identifier><identifier>PMID: 24047329</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Cardiovascular disease ; Chronic illnesses ; Diabetes ; Diabetics ; Disease control ; Disease prevention ; Disease susceptibility ; Distribution ; Estimates ; Health care industry ; Hypertension ; Intervention ; Lifestyles ; Medical care ; Medical geography ; Mortality ; Prevention ; Studies ; Subpopulations ; Type 2 diabetes ; United States</subject><ispartof>Population health metrics, 2013-09, Vol.11 (1), p.18-18, Article 18</ispartof><rights>COPYRIGHT 2013 BioMed Central Ltd.</rights><rights>2013 Gregg et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</rights><rights>Copyright © 2013 Gregg et al.; licensee BioMed Central Ltd. 2013 Gregg et al.; licensee BioMed Central Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c588t-159360304d2b46749536237bf4866a0d74612db41730732a918387b6782377ea3</citedby><cites>FETCH-LOGICAL-c588t-159360304d2b46749536237bf4866a0d74612db41730732a918387b6782377ea3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3853008/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3853008/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,728,781,785,865,886,27929,27930,53796,53798</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24047329$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gregg, Edward W</creatorcontrib><creatorcontrib>Boyle, James P</creatorcontrib><creatorcontrib>Thompson, Theodore J</creatorcontrib><creatorcontrib>Barker, Lawrence E</creatorcontrib><creatorcontrib>Albright, Ann L</creatorcontrib><creatorcontrib>Williamson, David F</creatorcontrib><title>Modeling the impact of prevention policies on future diabetes prevalence in the United States: 2010-2030</title><title>Population health metrics</title><addtitle>Popul Health Metr</addtitle><description>Although diabetes is one of the most costly and rapidly increasing serious chronic diseases worldwide, the optimal mix of strategies to reduce diabetes prevalence has not been determined.
Using a dynamic model that incorporates national data on diabetes prevalence and incidence, migration, mortality rates, and intervention effectiveness, we project the effect of five hypothetical prevention policies on future US diabetes rates through 2030: 1) no diabetes prevention strategy; 2) a "high-risk" strategy, wherein adults with both impaired fasting glucose (IFG) (fasting plasma glucose of 100-124 mg/dl) and impaired glucose tolerance (IGT) (2-hour post-load glucose of 141-199 mg/dl) receive structured lifestyle intervention; 3) a "moderate-risk" strategy, wherein only adults with IFG are offered structured lifestyle intervention; 4) a "population-wide" strategy, in which the entire population is exposed to broad risk reduction policies; and 5) a "combined" strategy, involving both the moderate-risk and population-wide strategies. We assumed that the moderate- and high-risk strategies reduce the annual diabetes incidence rate in the targeted subpopulations by 12.5% through 2030 and that the population-wide approach would reduce the projected annual diabetes incidence rate by 2% in the entire US population.
We project that by the year 2030, the combined strategy would prevent 4.6 million incident cases and 3.6 million prevalent cases, attenuating the increase in diabetes prevalence by 14%. The moderate-risk approach is projected to prevent 4.0 million incident cases, 3.1 million prevalent cases, attenuating the increase in prevalence by 12%. The high-risk and population approaches attenuate the projected prevalence increases by 5% and 3%, respectively. Even if the most effective strategy is implemented (the combined strategy), our projections indicate that the diabetes prevalence rate would increase by about 65% over the 23 years (i.e., from 12.9% in 2010 to 21.3% in 2030).
While implementation of appropriate diabetes prevention strategies may slow the rate of increase of the prevalence of diabetes among US adults through 2030, the US diabetes prevalence rate is likely to increase dramatically over the next 20 years. Demand for health care services for people with diabetes complications and diabetes-related disability will continue to grow, and these services will need to be strengthened along with primary diabetes prevention efforts.</description><subject>Cardiovascular disease</subject><subject>Chronic illnesses</subject><subject>Diabetes</subject><subject>Diabetics</subject><subject>Disease control</subject><subject>Disease prevention</subject><subject>Disease susceptibility</subject><subject>Distribution</subject><subject>Estimates</subject><subject>Health care industry</subject><subject>Hypertension</subject><subject>Intervention</subject><subject>Lifestyles</subject><subject>Medical care</subject><subject>Medical geography</subject><subject>Mortality</subject><subject>Prevention</subject><subject>Studies</subject><subject>Subpopulations</subject><subject>Type 2 diabetes</subject><subject>United States</subject><issn>1478-7954</issn><issn>1478-7954</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNptkktv1TAQhS0EoqWwZocssYFFWr9iOywqVRWPSkVIlK4tJ5nc6yqxg-1U8O9xaLn0IuSF7ZnvnNGMBqGXlBxTquUJFUpXqqlFRWlF9SN0uIs8fvA-QM9SuiGEsRJ6ig6YIEJx1hyi7efQw-j8BuctYDfNtss4DHiOcAs-u-DxHEbXOUi4vIclLxFw72wLuYRWzI7gu6L1vy2uvcvQ46tsS_4dZoSSihFOnqMngx0TvLi_j9D1h_ffzj9Vl18-XpyfXVZdrXWuaN1wWXDRs1ZIJZqaS8ZVOwgtpSW9EpKyvhVUcVI6sA3VXKtWKl0oBZYfodM733lpJ-i70kS0o5mjm2z8aYJ1Zj_j3dZswq3huuaE6GLw5t4ghu8LpGwmlzoYR-shLMlQUTe0VlKxgr7-B70JS_SlvZXSgmnOm7_UpkzKOD-EUrdbTc1ZzYWUjZBr2eP_UOX0MLkueBhcie8J3u4JCpPhR97YJSVzcfV1nz25Y7sYUoow7OZBiVkXyayrYtZVKV9DV8Wrh2Pc8X82h_8Cva--Fw</recordid><startdate>20130918</startdate><enddate>20130918</enddate><creator>Gregg, Edward W</creator><creator>Boyle, James P</creator><creator>Thompson, Theodore J</creator><creator>Barker, Lawrence E</creator><creator>Albright, Ann L</creator><creator>Williamson, David F</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>ISR</scope><scope>3V.</scope><scope>7T2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PATMY</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PYCSY</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20130918</creationdate><title>Modeling the impact of prevention policies on future diabetes prevalence in the United States: 2010-2030</title><author>Gregg, Edward W ; Boyle, James P ; Thompson, Theodore J ; Barker, Lawrence E ; Albright, Ann L ; Williamson, David F</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c588t-159360304d2b46749536237bf4866a0d74612db41730732a918387b6782377ea3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Cardiovascular disease</topic><topic>Chronic illnesses</topic><topic>Diabetes</topic><topic>Diabetics</topic><topic>Disease control</topic><topic>Disease prevention</topic><topic>Disease susceptibility</topic><topic>Distribution</topic><topic>Estimates</topic><topic>Health care industry</topic><topic>Hypertension</topic><topic>Intervention</topic><topic>Lifestyles</topic><topic>Medical care</topic><topic>Medical geography</topic><topic>Mortality</topic><topic>Prevention</topic><topic>Studies</topic><topic>Subpopulations</topic><topic>Type 2 diabetes</topic><topic>United States</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gregg, Edward W</creatorcontrib><creatorcontrib>Boyle, James P</creatorcontrib><creatorcontrib>Thompson, Theodore J</creatorcontrib><creatorcontrib>Barker, Lawrence E</creatorcontrib><creatorcontrib>Albright, Ann L</creatorcontrib><creatorcontrib>Williamson, David F</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>Natural Science Collection (ProQuest)</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Environmental Science Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>Environmental Science Collection</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Population health metrics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gregg, Edward W</au><au>Boyle, James P</au><au>Thompson, Theodore J</au><au>Barker, Lawrence E</au><au>Albright, Ann L</au><au>Williamson, David F</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Modeling the impact of prevention policies on future diabetes prevalence in the United States: 2010-2030</atitle><jtitle>Population health metrics</jtitle><addtitle>Popul Health Metr</addtitle><date>2013-09-18</date><risdate>2013</risdate><volume>11</volume><issue>1</issue><spage>18</spage><epage>18</epage><pages>18-18</pages><artnum>18</artnum><issn>1478-7954</issn><eissn>1478-7954</eissn><abstract>Although diabetes is one of the most costly and rapidly increasing serious chronic diseases worldwide, the optimal mix of strategies to reduce diabetes prevalence has not been determined.
Using a dynamic model that incorporates national data on diabetes prevalence and incidence, migration, mortality rates, and intervention effectiveness, we project the effect of five hypothetical prevention policies on future US diabetes rates through 2030: 1) no diabetes prevention strategy; 2) a "high-risk" strategy, wherein adults with both impaired fasting glucose (IFG) (fasting plasma glucose of 100-124 mg/dl) and impaired glucose tolerance (IGT) (2-hour post-load glucose of 141-199 mg/dl) receive structured lifestyle intervention; 3) a "moderate-risk" strategy, wherein only adults with IFG are offered structured lifestyle intervention; 4) a "population-wide" strategy, in which the entire population is exposed to broad risk reduction policies; and 5) a "combined" strategy, involving both the moderate-risk and population-wide strategies. We assumed that the moderate- and high-risk strategies reduce the annual diabetes incidence rate in the targeted subpopulations by 12.5% through 2030 and that the population-wide approach would reduce the projected annual diabetes incidence rate by 2% in the entire US population.
We project that by the year 2030, the combined strategy would prevent 4.6 million incident cases and 3.6 million prevalent cases, attenuating the increase in diabetes prevalence by 14%. The moderate-risk approach is projected to prevent 4.0 million incident cases, 3.1 million prevalent cases, attenuating the increase in prevalence by 12%. The high-risk and population approaches attenuate the projected prevalence increases by 5% and 3%, respectively. Even if the most effective strategy is implemented (the combined strategy), our projections indicate that the diabetes prevalence rate would increase by about 65% over the 23 years (i.e., from 12.9% in 2010 to 21.3% in 2030).
While implementation of appropriate diabetes prevention strategies may slow the rate of increase of the prevalence of diabetes among US adults through 2030, the US diabetes prevalence rate is likely to increase dramatically over the next 20 years. Demand for health care services for people with diabetes complications and diabetes-related disability will continue to grow, and these services will need to be strengthened along with primary diabetes prevention efforts.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>24047329</pmid><doi>10.1186/1478-7954-11-18</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1478-7954 |
ispartof | Population health metrics, 2013-09, Vol.11 (1), p.18-18, Article 18 |
issn | 1478-7954 1478-7954 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3853008 |
source | DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central Open Access; PubMed Central; Springer Nature OA/Free Journals; SpringerLink Journals - AutoHoldings |
subjects | Cardiovascular disease Chronic illnesses Diabetes Diabetics Disease control Disease prevention Disease susceptibility Distribution Estimates Health care industry Hypertension Intervention Lifestyles Medical care Medical geography Mortality Prevention Studies Subpopulations Type 2 diabetes United States |
title | Modeling the impact of prevention policies on future diabetes prevalence in the United States: 2010-2030 |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-13T02%3A09%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Modeling%20the%20impact%20of%20prevention%20policies%20on%20future%20diabetes%20prevalence%20in%20the%20United%20States:%202010-2030&rft.jtitle=Population%20health%20metrics&rft.au=Gregg,%20Edward%20W&rft.date=2013-09-18&rft.volume=11&rft.issue=1&rft.spage=18&rft.epage=18&rft.pages=18-18&rft.artnum=18&rft.issn=1478-7954&rft.eissn=1478-7954&rft_id=info:doi/10.1186/1478-7954-11-18&rft_dat=%3Cgale_pubme%3EA534669468%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1458428339&rft_id=info:pmid/24047329&rft_galeid=A534669468&rfr_iscdi=true |